Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACRS Aclaris Therapeutics

Post-Mkt 08-07 17:44:22 EDT

5.91

-0.18

-2.96%

盘后5.91

+0.000.00%

16:10 EDT

High6.23	Low5.65	Vol2.39M
Open6.08	D1 Closing6.09	Amplitude9.52%
Mkt Cap827.40M	Tradable Cap777.30M	Total Shares140.00M
T/O14.08M	T/O Rate1.82%	Tradable Shares131.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACRS","market":"US","secType":"STK","nameCN":"Aclaris Therapeutics","latestPrice":5.91,"timestamp":1786132800000,"preClose":6.09,"halted":0,"volume":2387946,"hourTrading":{"tag":"盘后","latestPrice":5.91,"preClose":5.91,"latestTime":"16:10 EDT","volume":14667,"amount":86681.97,"timestamp":1786133404495,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.029556650246305372,"floatShares":131523578,"shares":140000000,"eps":-0.561022,"marketStatus":"Post-Mkt","change":-0.18,"latestTime":"08-07 17:44:22 EDT","open":6.08,"high":6.23,"low":5.65,"amount":14075991,"amplitude":0.095238,"askPrice":6,"askSize":22,"bidPrice":5.52,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.561022,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1786147200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1444190400000,"exchange":"NASDAQ","adjPreClose":6.09,"preHourTrading":{"tag":"盘前","latestPrice":6.1501,"preClose":6.09,"latestTime":"09:15 EDT","volume":1018,"amount":6567.5492248,"timestamp":1786108510529,"change":0.0601,"changeRate":0.009869,"amplitude":0.095238},"postHourTrading":{"tag":"盘后","latestPrice":5.91,"preClose":5.91,"latestTime":"16:10 EDT","volume":14667,"amount":86681.97,"timestamp":1786133404495,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.814155,"impliedVol":1.0728,"impliedVolPercentile":0.3625},"requestUrl":"/m/hq/s/ACRS","defaultTab":"news","newsList":[{"id":"2657691996","title":"Aclaris Therapeutics Enters Amended At-the-Market Equity Sales Agreement with Leerink, Cantor","url":"https://stock-news.laohu8.com/highlight/detail?id=2657691996","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657691996?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:20","pubTimestamp":1786054830,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics enters amended at-the-market equity sales agreement with Leerink, CantorAclaris Therapeutics entered a second amended and restated at-the-market equity distribution agreement with","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL5NqhJn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNSH","BK4207","ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669800","title":"Aclaris Says FDA Grants Fast Track Status for Modzatinib in Moderate to Severe Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669800","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657669800?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:03","pubTimestamp":1786053813,"startTime":"0","endTime":"0","summary":"Aclaris says FDA grants Fast Track status for modzatinib in moderate to severe lichen planusAclaris Therapeutics received FDA Fast Track designation for modzatinib (ATI-2138) in moderate to severe lic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLRNL0j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657558666","title":"Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2657558666","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657558666?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:34","pubTimestamp":1786052040,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics said its modzatinib as a treatment for lichen planus received fast-track designation from the Food and Drug Administration.Lichen planus is an autoimmune disorder that can cause r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657466667","title":"Aclaris Therapeutics receives FDA Fast Track Designation for Modzatinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2657466667","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657466667?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:30","pubTimestamp":1786051834,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (ACRS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation for modzatinib for moderate to ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-receives-fda-fast-track-designation-for-modzatinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-receives-fda-fast-track-designation-for-modzatinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","ACRS","BK4007","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657665565","title":"Aclaris Therapeutics, Inc. Files for Mixed Shelf; Size not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2657665565","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657665565?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:09","pubTimestamp":1786050596,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN443266:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669805","title":"Aclaris Therapeutics, Inc.: Expects to Initiate a Phased Multi-Part Phase 2B Trial of Modzatinib in Lp in Q4 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657669805?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:35","pubTimestamp":1786048500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA57S5YH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657668436","title":"Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (Lp)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657668436","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657668436?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:35","pubTimestamp":1786048500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA57S5YH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657817637","title":"Craig-Hallum Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657817637","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657817637?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:38","pubTimestamp":1786023504,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Adam Vogel maintained a Buy rating on Aclaris Therapeutics today and set a price target of $10.00. Vogel covers the Healthcare...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-their-buy-rating-for-aclaris-therapeutics-acrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-their-buy-rating-for-aclaris-therapeutics-acrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639098","title":"Aclaris Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639098","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639098?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:29","pubTimestamp":1786019379,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings SummaryAclaris Therapeutics, Inc.ACRS.OQreported a quarterly adjusted loss of 15 cents per share for the quarter end","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638262","title":"Aclaris Q2 FY26 Net Loss Widens to $21.5 Million; Revenue Slips to $1.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638262","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638262?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:10","pubTimestamp":1786014630,"startTime":"0","endTime":"0","summary":"Aclaris Q2 FY26 net loss widens to $21.5 million; revenue slips to $1.6 millionAclaris posted a GAAP net loss of $21.5 million, widening from $15.4 million a year earlier; loss per share widened to $0","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL7JCxrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638230","title":"Aclaris Therapeutics Q2 Revenue Beats Analyst Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638230","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638230?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:10","pubTimestamp":1786014603,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Q2 revenue beats analyst estimatesOverviewU.S. biopharma's Q2 revenue fell yr/yr but beat analyst expectationsNet loss for Q2 widened and missed analyst estimatesCompany reaffirme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","BK0239","BK4007","BK0012","XNCR","BK4139","VNDA","BK0028","ELVN","300485","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638866","title":"Earnings Flash (ACRS) Aclaris Therapeutics Posts Q2 Net Loss $0.15 a Share, vs. FactSet Est of $0.16 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638866","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638866?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:03","pubTimestamp":1786014226,"startTime":"0","endTime":"0","summary":"Earnings Flash (ACRS) Aclaris Therapeutics Posts Q2 Net Loss $0.15 a Share, vs. FactSet Est of $0.16 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657468074","title":"Aclaris Therapeutics Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $1.629M Beat $1.383M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657468074","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657468074?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014015,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 6.25 percent. This is a 15.38 percent decrease over losses of $(0.13) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60986587/aclaris-therapeutics-q2-eps-0-15-beats-0-16-estimate-sales-1-629m-beat-1-383m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657809906","title":"Aclaris Therapeutics, - Expects Cash to Fund Operations Through End of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2657809906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657809906?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:59","pubTimestamp":1786013940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXKCHZKX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680918","title":"Aclaris Therapeutics Q2 Net Income USD -21.505 Million VS. Ibes Estimate USD -21.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680918","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680918?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:59","pubTimestamp":1786013940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXKCHZKX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680999","title":"Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680999","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680999?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:59","pubTimestamp":1786013940,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUAVGDQ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656374059","title":"Aclaris Therapeutics Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656374059","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656374059?lang=en_us&edition=fundamental","pubTime":"2026-08-03 21:45","pubTimestamp":1785764720,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc <ACRS.OQ> expected to post a loss of16cents a share - Earnings PreviewAclaris Therapeutics IncACRS.OQACRS.Ois expected to  show a fall in quarterly revenue when it reports  re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4401IN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651606164","title":"Aclaris Publishes Corporate Presentation Outlining Inflammatory and Immunology Pipeline, 2026 Clinical Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2651606164","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651606164?lang=en_us&edition=fundamental","pubTime":"2026-07-16 01:38","pubTimestamp":1784137114,"startTime":"0","endTime":"0","summary":"Aclaris publishes corporate presentation outlining inflammatory and immunology pipeline, 2026 clinical catalystsAclaris outlined three 2026 pipeline catalysts across its inflammation and immunology po","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL8W7JXc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644764071","title":"Aclaris Therapeutics management to meet with Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2644764071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644764071?lang=en_us&edition=fundamental","pubTime":"2026-06-17 02:40","pubTimestamp":1781635211,"startTime":"0","endTime":"0","summary":"Meeting to be held on June 16 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-management-to-meet-with-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-management-to-meet-with-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","ACRS","OPY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641640121","title":"Aclaris Therapeutics stockholders approve 2026 executive pay plan in advisory vote","url":"https://stock-news.laohu8.com/highlight/detail?id=2641640121","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641640121?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:02","pubTimestamp":1780603343,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics held its annual shareholder meeting on June 4, 2026.Shareholders selected two directors to serve through the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL3k4rW4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclaristx.com","stockEarnings":[{"period":"1week","weight":0.1447},{"period":"1month","weight":0.0836},{"period":"3month","weight":0.2353},{"period":"6month","weight":0.7059},{"period":"1year","weight":2.929},{"period":"ytd","weight":1.0233}],"compareEarnings":[{"period":"1week","weight":0.0362},{"period":"1month","weight":0.0279},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.1129},{"period":"1year","weight":0.2146},{"period":"ytd","weight":0.1271}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.145543},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.038718},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.021975},{"month":4,"riseRate":0.454545,"avgChangeRate":0.005147},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.034939},{"month":6,"riseRate":0.636364,"avgChangeRate":0.010279},{"month":7,"riseRate":0.545455,"avgChangeRate":0.007544},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.002274},{"month":9,"riseRate":0.4,"avgChangeRate":0.026634},{"month":10,"riseRate":0.4,"avgChangeRate":0.132278},{"month":11,"riseRate":0.363636,"avgChangeRate":0.075295},{"month":12,"riseRate":0.727273,"avgChangeRate":0.092435}],"exchange":"NASDAQ","name":"Aclaris Therapeutics","nameEN":"Aclaris Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aclaris Therapeutics,ACRS,Aclaris Therapeutics股票,Aclaris Therapeutics股票老虎,Aclaris Therapeutics股票老虎国际,Aclaris Therapeutics行情,Aclaris Therapeutics股票行情,Aclaris Therapeutics股价,Aclaris Therapeutics股市,Aclaris Therapeutics股票价格,Aclaris Therapeutics股票交易,Aclaris Therapeutics股票购买,Aclaris Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}